Production (Stage)
Adlai Nortye Ltd.
ANL
$1.85
$0.04262.36%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/30/2025
-
MarketBeat
4/10/2025
-
GuruFocus
4/10/2025
-
Globe Newswire
3/14/2025
-
MarketBeat
2/14/2025
-
MarketBeat
2/3/2025
-
Simply Wall St
1/31/2025
-
MarketBeat
1/29/2025
-
MarketBeat
1/27/2025
-
Ticker Report
1/14/2025
-
MarketBeat
12/31/2024
-
TipRanks Financial Blog
12/31/2024
-
Ticker Report
12/29/2024
-
MarketBeat
11/30/2024
-
MarketBeat
11/11/2024
-
MarketBeat - AP News
11/10/2024
-
Simply Wall St
11/7/2024
-
Ticker Report
10/26/2024
-
MarketBeat - AP News
10/21/2024
-
Ticker Report
10/18/2024
-
MarketBeat - AP News
9/26/2024
-
Ticker Report
9/26/2024
-
MarketBeat - AP News
9/9/2024
-
Zacks Investment Research
Adlai Nortye Ltd. to Post FY2024 Earnings of ($0.88) Per Share, HC Wainwright Forecasts (NASDAQ:ANL)
9/7/2024
-
Ticker Report
9/6/2024
-
Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Wednesday, April 30, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
End of April (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
848-230-7430
Address
Ugland House
Grand Cayman, KY1-1104
Grand Cayman, KY1-1104
Country
Year Founded
Business Description
Sector
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase...
more